Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  lenalidomide
Find trials that include:  Any drugs shown
Results 1-25 of 105 for your search:
Start Over
Lenalidomide or Observation in Treating Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E3A06, NCI-2011-02057, CDR0000682012, ECOG-E3A06, NCT01169337
Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662
Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E1A11, NCI-2012-02608, ECOG-E1A11, NCT01863550
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-007, NCI-2014-02022, NCT01938001
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-008, NCI-2015-00708, NCT01996865
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR104762, NCI-2015-01114, 2014-002273-11, 54767414MMY3008, NCT02252172
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 80
Trial IDs: CC-5013-DLC-002, NCI-2015-00282, 2013-004054-21, NCT02285062
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Status: Active
Phase: Phase III
Type: Natural history/Epidemiology
Age: 18 to 70
Trial IDs: BMTCTN07LT, NCI-2015-01752, U01HL069294-05, NCT02322320
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C16011, NCI-2012-02752, 2011-005468-10, C16011-CTIL, NL41603.028.12, U1111-1164-7621, NCT01659658
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A061402, NCI-2015-00323, NCT02516423
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-185, NCI-2015-01851, 163239, 2015-002901-12, NCT02579863
Lenalidomide with or without Carfilzomib and Dexamethasone in Treating Patients with Multiple Myeloma after Stem-Cell Transplant
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB15-1286, NCI-2016-00079, NCT02659293
Lenalidomide, Rituximab, Cyclophosphamide, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Diffuse Large Cell or Grade 3A/B Follicular B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC078E, NCI-2009-01196, Celgene #RV-NHL-PI-0325, RV-NHL-PI-0325, MAYO-MC078E, NCT00670358
Lenalidomide and AT-101 in Treating Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC128A, NCI-2009-01569, NCT01021345, NCT01003769
Lenalidomide, High-Dose Melphalan, and Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0290, NCI-2010-01423, NCT01142232
Donor Peripheral Blood Stem Cell transplantation Followed by Lenalidomide and Sirolimus in Treating Patients With High-Risk Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 70
Trial IDs: IUCRO-0307, NCI-2011-00266, 1012-24, 1105005328, NCT01303965
Vaccine Therapy and Lenalidomide in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: H-30087, NCI-2013-01015, RV-CLL-PI-0715, TAIL, NCT01604031
Bortezomib, Dexamethasone, and Lenalidomide with or without Elotuzumab in Treating Patients with Newly Diagnosed High-Risk Multiple Myeloma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1211, NCI-2012-01998, CDR0000738512, PS1211_A12PAMDREVW01, SWOG-S1211, NCT01668719
Umbilical Cord Blood-Derived Natural Killer Cells, Lenalidomide, High-Dose Melphalan, and Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 2011-0379, NCI-2014-01096, NCI-2014-00541, RV-MM-PI-0691, NCT01729091
Carfilzomib, Lenalidomide and Rituximab in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0188, NCI-2014-01201, NCI-2013-00117, NCT01729104
Lenalidomide and Romidepsin with or without Dexamethasone in Treating Patients with Recurrent or Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma, or Multiple Myeloma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 1112009392, NCI-2015-00921, RM-PTCL-PI-0021, NCT01742793
Romidepsin and Lenalidomide in Treating Patients with Relapsed or Refractory Lymphoma or Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-170, NCI-2013-00005, NCT01755975
Lenalidomide and Obinutuzumab in Treating Patients with Relapsed Low-Grade Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0261, NCI-2014-00943, ML28301, NCT01995669
Lenalidomide in Treating Older Patients with Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 to 75
Trial IDs: 13-08-148, NCI-2013-02493, NCT02038153
Start Over